Intrathecal Narcotic use in Gynecologic Oncology: Safety and Impact on Postoperative Length of Stay
- *Corresponding Author:
- Sarah Goodrich, MD
Gynecologic Oncology, Cleveland Clinic Foundation
9500 Euclid Ave, Desk A81, Cleveland, OH 44106, USA
Tel: 216 444-4884
Fax: 216 636-1296
E-mail: [email protected]
Received date: August 16, 2012; Accepted date: September 18, 2012; Published date: September 28, 2012
Citation: Goodrich S, Francis C, Isaacs M, Moore E, Angermeier SM, et al. (2012) Intrathecal Narcotic Use in Gynecologic Oncology: Safety and Impact on Postoperative Length of Stay. J Anesth Clin Res 3:241. doi: 10.4172/2155-6148.1000241
Copyright: © 2012 Chuy K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: The objective of this study was to determine how intrathecal narcotic use impacts the postoperative course of patients undergoing major gynecologic oncologic procedures. The endpoints evaluated were toxicity and postoperative length of stay. Methods: This was a retrospective chart review of 598 patients who underwent major abdominal surgery and received intrathecal narcotics for post-operative pain control during a 49 month period at St. Vincent Hospital. Charts were reviewed to determine the incidence of specific toxicities and postoperative length of stay.